Tags

Type your tag names separated by a space and hit enter

Vaginal microbicides to prevent human immunodeficiency virus infection in women: perspectives on the female genital tract, sexual maturity and mucosal inflammation.
Best Pract Res Clin Obstet Gynaecol. 2012 Aug; 26(4):441-9.BP

Abstract

Topically applied vaginal microbicides to protect against human immunodeficiency (HIV) virus infection offer an important female-controlled prevention strategy. Microbicides have been in development for more than 2 decades, and have included various agents that disrupt cellular and microbial membranes (surfactants), restore the natural acidic protective pH of the vagina (acid buffers), and those that interfere with interactions between HIV envelope proteins and cellular receptors (anionic polymers). Although none of these candidate microbicides have shown significant protection against HIV in clinical trials, a topical gel, including the antiretroviral drug tenofovir (TFV) 1% was the first microbicide to be tested to show some protection against HIV infection. This review explores the effect of female genital tract biology and anatomy, mucosal inflammation, and age on the effectiveness of microbicides to prevent HIV infection.

Authors+Show Affiliations

Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22429786

Citation

Roberts, Lindi, et al. "Vaginal Microbicides to Prevent Human Immunodeficiency Virus Infection in Women: Perspectives On the Female Genital Tract, Sexual Maturity and Mucosal Inflammation." Best Practice & Research. Clinical Obstetrics & Gynaecology, vol. 26, no. 4, 2012, pp. 441-9.
Roberts L, Liebenberg L, Barnabas S, et al. Vaginal microbicides to prevent human immunodeficiency virus infection in women: perspectives on the female genital tract, sexual maturity and mucosal inflammation. Best Pract Res Clin Obstet Gynaecol. 2012;26(4):441-9.
Roberts, L., Liebenberg, L., Barnabas, S., & Passmore, J. A. (2012). Vaginal microbicides to prevent human immunodeficiency virus infection in women: perspectives on the female genital tract, sexual maturity and mucosal inflammation. Best Practice & Research. Clinical Obstetrics & Gynaecology, 26(4), 441-9. https://doi.org/10.1016/j.bpobgyn.2012.02.002
Roberts L, et al. Vaginal Microbicides to Prevent Human Immunodeficiency Virus Infection in Women: Perspectives On the Female Genital Tract, Sexual Maturity and Mucosal Inflammation. Best Pract Res Clin Obstet Gynaecol. 2012;26(4):441-9. PubMed PMID: 22429786.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vaginal microbicides to prevent human immunodeficiency virus infection in women: perspectives on the female genital tract, sexual maturity and mucosal inflammation. AU - Roberts,Lindi, AU - Liebenberg,Lenine, AU - Barnabas,Shaun, AU - Passmore,Jo-Ann, Y1 - 2012/03/17/ PY - 2012/01/22/received PY - 2012/02/23/accepted PY - 2012/3/21/entrez PY - 2012/3/21/pubmed PY - 2012/10/17/medline SP - 441 EP - 9 JF - Best practice & research. Clinical obstetrics & gynaecology JO - Best Pract Res Clin Obstet Gynaecol VL - 26 IS - 4 N2 - Topically applied vaginal microbicides to protect against human immunodeficiency (HIV) virus infection offer an important female-controlled prevention strategy. Microbicides have been in development for more than 2 decades, and have included various agents that disrupt cellular and microbial membranes (surfactants), restore the natural acidic protective pH of the vagina (acid buffers), and those that interfere with interactions between HIV envelope proteins and cellular receptors (anionic polymers). Although none of these candidate microbicides have shown significant protection against HIV in clinical trials, a topical gel, including the antiretroviral drug tenofovir (TFV) 1% was the first microbicide to be tested to show some protection against HIV infection. This review explores the effect of female genital tract biology and anatomy, mucosal inflammation, and age on the effectiveness of microbicides to prevent HIV infection. SN - 1532-1932 UR - https://www.unboundmedicine.com/medline/citation/22429786/Vaginal_microbicides_to_prevent_human_immunodeficiency_virus_infection_in_women:_perspectives_on_the_female_genital_tract_sexual_maturity_and_mucosal_inflammation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1521-6934(12)00049-1 DB - PRIME DP - Unbound Medicine ER -